8 Stocks Under $10 to Trade for Huge Profits

As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert to my subscribers in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Rennova Health

  • Thursday's Range: $0.23-$0.25
  • 52-Week Range: $0.22-$8.00
  • Thursday's Volume: 1.19 million
  • Three-Month Average Volume: 1.14 million

Rennova Health  (RNVA) , provides diagnostics and supportive software solutions to health care providers in the U.S. This stock closed up 1.1% to 25 cents per share in Thursday's trading session.

From a technical perspective, Rennova Health spiked modestly higher on Thursday right above its new 52-week low of 22 cents per share with decent upside volume flows. This stock has been downtrending badly over the last two months, with shares collapsing off its high of $1.16 a share to its new 52-week low of 22 cents per share. During that downtrend, shares of Rennova Health have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock is now starting to trend a bit higher off that 22 cents low, and it's quickly moving within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at 26 to 27 cents per share with high volume.

Traders should now look for long-biased trades in Rennova Health as long as it's trending above its new 52-week low of 22 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.14 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at 30 to 32 cents per share. Any high-volume move above 32 cents per share will then push this stock into its previous gap-down-day zone that started near 74 cents per share.

uniQure

  • Thursday's Range: $6.91-$7.32
  • 52-Week Range: $6.68-$36.38
  • Thursday's Volume: 294,000
  • Three-Month Average Volume: 300,265

uniQure  (QURE) , a biopharmaceutical company, engages in the discovery, development and commercialization of gene therapies in the Netherlands. This stock closed up 1.9% to $7.28 in Thursday's trading session.

From a technical perspective, uniQure spiked modestly higher on Thursday right above its new 52-week low of $6.68 a share with decent upside volume flows. This stock broke below its previous 52-week low of $6.75 a share on Wednesday, but managed to rally higher and close above $7 a share with strong upside volume flows. This bump to the upside on Thursday is now quickly pushing shares of uniQure within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to clear its 20-day moving average of $7.46 a share and then once it takes out more near-term overhead resistance levels at $7.57 to $7.77 a share with high volume.

Traders should now look for long-biased trades in uniQure as long as it's trending above Thursday's intraday low of $6.91 a share or above its new 52-week low of $6.68 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 300,265 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $8.24, or even $9 to its 50-day moving average of $9.48 a share.

Tokai Pharmaceuticals

  • Thursday's Range: $1.01-$1.33
  • 52-Week Range: $1.01-$14.22
  • Thursday's Volume: 8.80 million
  • Three-Month Average Volume: 248,443

Tokai Pharmaceuticals  (TKAI) , a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. This stock closed up 14.8 % to $1.24 in Thursday's trading session.

From a technical perspective, Tokai Pharmaceuticals exploded sharply higher on Thursday off its new 52-week low of $1.01 a share with monster upside volume flows. This stock recently gapped-down sharply lower from around $5 a share to under $1.50 a share with heavy downside volume flows. Following that move, shares of Tokai Pharmaceuticals have now started to rebound off its new 52-week low and off extremely oversold levels, since its current relative strength index reading is 17.8.

Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from once volume buyers show up. Market players should now look for a continuation move to the upside in the short-term if this stock manages to take out Thursday's intraday high of $1.33 a share with strong volume.

Traders should now look for long-biased trades in Tokai Pharmaceuticals as long as it's trending above $1.10 a share or above Thursday's intraday low of $1.01 a share and then once it sustains a move or close above Thursday's intraday high of $1.33 a share with volume that hits near or above 248,443 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its recent gap-down-day high near $1.75 a share. Any high-volume move above $1.75 will then give this stock a chance to make a run at $2 to $2.50 a share.

Adverum Biotechnologies

  • Thursday's Range: $3.29-$3.78
  • 52-Week Range: $2.99-$15.63
  • Thursday's Volume: 1.55 million
  • Three-Month Average Volume: 218,440

Adverum Biotechnologies  (ADVM) , a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. This stock closed up 8.7% to $3.62 in Thursday's trading session.

From a technical perspective, Adverum Biotechnologies ripped sharply higher on Thursday right above its 20-day moving average of $3.22 a share and into its 50-day moving average of $3.62 a share with strong upside volume flows. This high-volume rip to the upside also pushed this stock into breakout territory, since it managed to clear some near-term overhead resistance at $3.50 a share. Market players should now look for a continuation move to the upside in the short-term if shares of Adverum Biotechnologies manages to clear Thursday's intraday high of $3.78 a share with strong upside volume flows.

Traders should now look for long-biased trades in Adverum Biotechnologies as long as it's trending above $3.50 a share or above Thursday's intraday low of $3.29 a share and then once it sustains a move or close above Thursday's intraday high of $3.78 a share with volume that hits near or above 218,440 shares. If this move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.20, or even $4.50 to $4.70 a share.

Tengasco

  • Thursday's Range: $0.88-$1.05
  • 52-Week Range: $0.60-$5.80
  • Thursday's Volume: 160,000
  • Three-Month Average Volume: 121,292

Tengasco  (TGC) , together with its subsidiaries, engages in the exploration for and production of oil and natural gas in the U.S. This stock closed up 14.4% to $1.03 in Thursday's trading session.

From a technical perspective, Tengasco ripped sharply higher on Thursday right above its 50-day moving average of 85 cents per share and back above its 20-day moving average of 91 cents per share with decent upside volume flows. This high-volume spike to the upside is now quickly pushing shares of Tengasco within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out Thursday's intraday high of $1.05 a share and then once it clears more near-term resistance at $1.09 a share with high volume.

Traders should now look for long-biased trades in Tengasco as long as it's trending above its 20-day moving average of 91 cents per share or above its 50-day moving average of 85 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 121,292 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out is next major overhead resistance levels at near $1.30 to its 200-day moving average of $1.42, or even $1.52 to $1.60 a share.

BioCryst Pharmaceuticals

  • Thursday's Range: $3.30-$3.49
  • 52-Week Range: $1.63-$15.96
  • Thursday's Volume: 1.03 million
  • Three-Month Average Volume: 698,898

BioCryst Pharmaceuticals  (BCRX) , a biotechnology company, designs, optimizes and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. This stock closed up 1.4% to $3.46 in Thursday's trading session.

From a technical perspective, BioCryst Pharmaceuticals trended modestly higher on Thursday right above its 50-day moving average of $3.12 a share with strong upside volume flows. This stock has been uptrending over the last two months, with shares moving higher off its low of $2.60 a share to its intraday high on Thursday of $3.49 a share. During that uptrend, shares of BioCryst Pharmaceuticals have been making mostly higher lows and higher highs, which is bullish technical price action. Market players should now look for a continuation move to the upside in the short-term if this stock manages to clear Thursday's intraday high of $3.49 a share with strong volume.

Traders should now look for long-biased trades in BioCryst Pharmaceuticals as long as it's trending above Thursday's intraday low of $3.30 a share or above its 50-day moving average of $3.12 a share and then once it sustains a move or close above Thursday's intraday high of $3.49 a share with volume that hits near or above 698,898 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at $4.03 a share. Any high-volume move above $4.03 will then give this stock a chance to re-fill some of its previous gap-down-day zone from February that started near $7 a share.

Scorpio Tankers

  • Thursday's Range: $4.35-$4.89
  • 52-Week Range: $4.05-$10.98
  • Thursday's Volume: 10.29 million
  • Three-Month Average Volume: 2.62 million

Scorpio Tankers  (STNG) , together with its subsidiaries, engages in the seaborne transportation of refined petroleum products and crude oil worldwide. This stock closed up 10.1% to $4.78 in Thursday's trading session.

From a technical perspective, Scorpio Tankers exploded higher on Thursday right above some near-term support at $4.31 a share and back above its 20-day moving average of $4.48 a share with monster upside volume flows. This high-volume rip to the upside is now quickly pushing shares of Scorpio Tankers within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $4.89 a share to its 50-day moving average of $4.93 a share and then above more resistance around $5 a share with high volume.

Traders should now look for long-biased trades in Scorpio Tankers as long as it's trending above its 20-day moving average of $4.48 a share or above more key support at $43.31 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 2.62 million shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $5.20 to $5.50, or even $5.80 to $6 a share.

Repros Therapeutics

  • Thursday's Range: $1.71-$1.85
  • 52-Week Range: $0.80-$8.96
  • Thursday's Volume: 224,000
  • Three-Month Average Volume: 488,497

Repros Therapeutics  (RPRX) , a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the U.S. This stock closed up 5.8% to $1.80 in Thursday's trading session.

From a technical perspective, Repros Therapeutics spiked sharply higher on Thursday back above both its 50-day moving average of $1.77 a share and its 200-day moving average of $1.79 a share with lighter-than-average volume. This bump to the upside is now quickly pushing shares of Repros Therapeutics within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $1.85 to $1.90 a share and then once it clears more key resistance levels at $2 to $2.02 a share with high volume.

Traders should now look for long-biased trades in Repros Therapeutics as long as it's trending above Thursday's intraday low of $1.71 a share or above more near-term resistance at $1.66 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 488,497 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.25 to $2.70, or even $3 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

More from Opinion

Tuesday Turnaround: Micron, Autonomous Driving, and J.C. Penney

Tuesday Turnaround: Micron, Autonomous Driving, and J.C. Penney

Cable Stock Investors Should Keep an Eye On Wireless Broadband's Rise

Cable Stock Investors Should Keep an Eye On Wireless Broadband's Rise

Trump Blinks on China Trade War That's Looking Harder to Win

Trump Blinks on China Trade War That's Looking Harder to Win

Monday Madness: GE, China, and Micron

Monday Madness: GE, China, and Micron

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly